Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs.
Serum interleukin-1 beta (IL-1 beta) and soluble interleukin-2 receptor (sIL-2R) levels were examined in patients with hyperthyroidism due to Graves' disease (GD) and toxic nodular goitre (TNG) before and during antithyroid drug therapy. A total of 32 patients were studied; 23 patients (14 with GD and nine with TNG) were in a hyperthyroid state (group A) and nine patients (four with GD and five with TNG) were in a euthyroid state, under carbimazole or methimazole treatment (group B). Ten hyperthyroid patients from group A (seven with GD and three with TNG) were also examined while euthyroid on treatment (Subgroup A). Serum was taken from all patients for the measurement of sIL-2R, IL-1 beta, total T4 (TT4), total T3 (TT3) and TSH concentrations. The results were compared with those from 30 normal controls. Serum sIL-2R levels were higher in Group A (671.3 +/- 74.0 U mL-1, mean +/- SE), than in Group B (214.1 +/- 61.8 U mL-1) and controls (149 +/- 14.8 U mL-1), P < 0.001. Similarly, the subgroup of 10 patients had higher levels of sIL-2R during the hyperthyroid phase than while euthyroid (P < 0.001). There was a positive correlation between sIL-2R values and levels of T4 and T3. In contrast, serum IL-1 beta levels were higher in Group B patients (197.5 +/- 39.2 pg mL-1) compared with those in Group A (66.5 +/- 17 pg mL-1, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000627:therapeutic use*; D005260:Female; D006042:Goiter / Q000097:blood; D006111:Graves Disease / Q000097:blood; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000188:drug therapy; D007375:Interleukin-1 / Q000097:blood* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000032:analysis
D013956:Antithyroid Agents; D007375:Interleukin-1; D015375:Receptors, Interleukin-2